KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Assets (2018 - 2025)

BioNTech SE's Assets history spans 8 years, with the latest figure at $25.6 billion for Q4 2025.

  • On a quarterly basis, Assets rose 6.32% to $25.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $25.6 billion, a 6.32% increase, with the full-year FY2025 number at $24.8 billion, up 3.19% from a year prior.
  • Assets hit $25.6 billion in Q4 2025 for BioNTech SE, up from $24.9 billion in the prior quarter.
  • Over the last five years, Assets for BNTX hit a ceiling of $25.6 billion in Q4 2025 and a floor of $5.1 billion in Q1 2021.
  • Historically, Assets has averaged $21.7 billion across 5 years, with a median of $23.8 billion in 2022.
  • Biggest five-year swings in Assets: skyrocketed 927.56% in 2021 and later fell 7.85% in 2025.
  • Tracing BNTX's Assets over 5 years: stood at $18.1 billion in 2021, then soared by 31.15% to $23.8 billion in 2022, then rose by 4.22% to $24.8 billion in 2023, then decreased by 2.74% to $24.1 billion in 2024, then rose by 6.32% to $25.6 billion in 2025.
  • Business Quant data shows Assets for BNTX at $25.6 billion in Q4 2025, $24.9 billion in Q3 2025, and $24.5 billion in Q2 2025.